Retinal vein occlusion therapy options widen past first-generation anti-VEGF
Faricimab and high-dose aflibercept extension, structured macular edema management, and emerging mechanism programs are reshaping retinal vein occlusion management.
Retinal vein occlusion (RVO) macular edema has been a ranibizumab and aflibercept anti-VEGF category with intravitreal corticosteroid implants in selected cases. Faricimab (Ang-2 plus VEGF-A) carries RVO indication, high-dose aflibercept extends dosing intervals, and emerging mechanism programs targeting alternative pathways are reading out. The systemic-care integration (RVO is associated with cardiovascular risk factors that benefit from structured workup) is the broader care-pathway dimension.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- ExplainedWhat is presbyopia?
- SnapshotPresbyopia therapy reference (2026)